CD95 _ FAS pTyr232
- Known as:
- CD95 _ Fas Cell Surface Death Receptor pTyr232
- Catalog number:
- AP12873PU-N
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- CD95 _ FAS pTyr232
Related genes to: CD95 _ FAS pTyr232
- Gene:
- FAS NIH gene
- Name:
- Fas cell surface death receptor
- Previous symbol:
- FAS1, APT1, TNFRSF6
- Synonyms:
- CD95, APO-1
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD95 _ FAS pTyr232
Related articles to: CD95 _ FAS pTyr232
- - Source: PubMed
Publication date: 2026/08/28
Moura Priscila AQuek Swee-PeckCardoso Márcio ZKronforst Marcus R - No therapies directly block apoptosis in tissue injury or the many diseases driven by cell loss. The BCL-2 family protein BAX is a central mediator of this pathway and C126 resides within a key regulatory region where physiologic or pharmacologic ligands can activate or inhibit its function. Here, we report enantioselective covalent BAX inhibitors that site-specifically react with C126 and confer cytoprotection across multiple cell types. These ligands constrain BAX conformation and suppress apoptosis in a strictly BAX-dependent manner. Medicinal chemistry optimization yielded covalent BAX inhibitor 3 (CBI-3), an analog with pharmacokinetics suitable for in vivo studies. In a murine model of Fas-induced fulminant hepatic failure, CBI-3 reduced hepatocyte apoptosis and preserved liver histology and survival. CBI-3 also conferred cytoprotection of motor neurons derived from human induced pluripotent stem cells of healthy and amyotrophic lateral sclerosis donors. These findings establish covalent BAX inhibition as a therapeutic strategy to directly block pathologic cell death. - Source: PubMed
Publication date: 2026/08/28
Shi PeiwenMelillo BrunoMcHenry Matthew WCamara Christina MYang KaNjomen EvertGodes MarinaPazyra-Murphy Maria FBranch Mary RoseTesar BethanySegal Rosalind ARubin Lee LCameron Michael DBird Gregory HWales Thomas EGygi Steven PCravatt Benjamin FWalensky Loren D - Renal cell carcinoma (RCC) is known for its propensity for distant metastasis, including skeletal involvement; however, metastatic spread to the foot, particularly the calcaneus and talus, is exceptionally rare, with fewer than 15 cases documented in the literature. We report a 59-year-old woman with a history of RCC treated with partial nephrectomy 7 years earlier who presented with 6 months of progressive left foot pain initially attributed to plantar fasciitis. Over the course of 4 emergency department visits spanning approximately 1 month, her oncologic history was not incorporated into the differential diagnosis. Advanced imaging ultimately revealed a 6.2 cm × 6.0 cm × 5.2 cm enhancing soft tissue mass infiltrating both the calcaneus and talus. Histopathology confirmed metastatic clear cell RCC. Given the extent of osseous destruction precluding viable reconstruction, the patient underwent below-knee amputation. Staging identified a concurrent pulmonary lesion, and postoperative systemic immunotherapy was initiated, though interval imaging demonstrated disease progression. This case highlights the diagnostic pitfalls of atypical RCC metastasis and underscores that a prolonged disease-free interval following nephrectomy should not diminish clinical suspicion. Inclusion of metastatic disease in the differential for refractory foot pain in any patient with an oncologic history is essential to enable timely diagnosis and preserve limb-salvage options.Levels of Evidence:Study Design:Diagnostic case study (Level V); structured single-case analysis with systematic review of the published literature. - Source: PubMed
Publication date: 2026/08/28
Abdul Rahman Hana QAtwater Lara C - BackgroundBöhler's and Gissane's angles are used in calcaneal fracture assessment, but measurement consistency varies. ImageJ may offer a low-cost alternative to Picture Archiving and Communication System (PACS). This study aimed to define margin of error (MOE) and evaluate whether ImageJ provides measurement agreement and reliability comparable to PACSMethodsMargin of error was predefined based on previously reported variability and expert consensus. Three observers measured Böhler's and Gissane's angles on 42 radiographs using PACS and ImageJ; a consensus PACS measurement served as the reference measurement. Reliability (intraclass correlation coefficient), deviation from the consensus reference (mean/median absolute error; bias), agreement within MOE, and Bland-Altman analyses were performed.ResultsThe predefined margins of error were ±2.5° (Böhler) and ±5° (Gissane). Interobserver reliability was good to excellent for Böhler and poor to moderate for Gissane. Within-observer inter-method agreement was excellent for Böhler and variable for Gissane. Deviations for Gissane frequently exceeded the MOE, with minimal method bias.ConclusionImageJ performed comparably to PACS for Böhler's angle measurements. However, Gissane's angle demonstrated poor reproducibility with both methods, likely due to anatomical and projectional factors.Level of evidence:. - Source: PubMed
Publication date: 2026/08/28
Te Boekhorst RicoHalm Jens AHemke RobertSchepers Tim - BackgroundFoot and ankle training has evolved with the development of the fellowship curriculum. Increased specialization has enhanced management of foot and ankle pathology. Despite this, physician marketing schemes have clouded this definition.PurposeThe purpose of this study was to review and compare current foot and ankle fellowship programs (podiatric and orthopaedic) to better define what a surgical foot and ankle fellowship is, thereby more appropriately delineating between that of a preceptorship.Study Design/ MethodsA digital search was performed through online published American Orthopedic Foot and Ankle Society (AOFAS) and American College of Foot and Ankle Surgeons (ACFAS) fellowship programs. Number of programs, case volume, faculty demographics, and duration (years) were all recorded.ResultsWe identified 51 total orthopaedic programs compared with 62 podiatric programs. Both societies defined a fellowship as a year-long experience. Each had a large attending faculty-to-fellow ratio [median of 3-1 orthopaedics and 6-1 podiatric, respectively]. Average case volume digitally published per year was on average 680 (±128) cases for orthopaedics and 481 (±123) for podiatric programs. However, publishable data are scarce and hard to prove.ConclusionThe foot and ankle community should continue to vet and differentiate what constitutes "fellowship training." Improved publicly available data would allow better transparency of different types of extended training. Further studies are warranted to provide a clearer definition of "fellowship" training, thereby maintaining quality control and preventing false advertising.Level of Evidence:Level IV. - Source: PubMed
Publication date: 2026/08/28
Hyer ChristopherMeyer CameronKim Jae YoonMartinez Orlando